Genetic engineering of lymphocytes to express a transgenic T ceil receptor (TCR) specific for a defined melanoma antigen allows the efficient generation of large populations of antigen-specific T cells suitable for T cell adoptive immunotherapy. These engineered cells can be additionally genetically labeled with a positron emitting tomography (PET) reporter gene to allow the non-invasive study of the in vivo kinetics of antitumor T cell responses. In this second revised project we propose a clinical trial incorporating advances from our ongoing preclinical studies. We propose to deplete CD25+ cells (including natural T regulatory -nTreg- cells) before activation and to transduce peripheral blood mononuclear cells (PBMC, including both CD8+ and CD4+ T cells) with a high affinity TCR to the melanoma tumor rejection antigen MART-1 using a lentiviral vector. We will follow the bio-distribution and persistence of adoptively transferred, transduced PBMC in vivo via PETbased imaging and relate this to their functional activity, assessed by cutting edge immunoassays.
Aim 1 will be a phase I dose escalation clinical trial that will test the safety and feasibility of adoptive transfer of MART-1 TCR transgenic CD8+ and CD4+ T cells to patients with metastatic melanoma. All patients will be HLA-A2.1 positive and have MART-1 expressing melanoma. Two cohorts of 6 patients will have received a lymphodepleting or myelodepleting chemo-irradiation regimen to study how to fully exploit post-conditioning homeostatic T cell proliferation. Following adoptive TCR transgenic cell transfer, patients will receive MART-1- specific in vivo boosting with dendritic cell (DC) vaccines together with high dose interleukin-2 (IL-2) to foster additional antigen-driven expansion. Patients in the myelodepleting cohort will receive hematopoietic support with the reinfusion of CD34-purified peripheral blood stem cells (PBSC).
In Aim 2 we will examine the impact of the conditioning regimen and the infused TCR transgenic cell phenotype on the ex vivo expansion, persistence, phenotype and function of MART-1 TCR transgenic CD8+ T cells recovered from patients. We hypothesize that the T cell subpopulations that are able to sustain long-term persistence (naive and central memory T cells) will have adequate systemic distribution, tumor targeting and antitumor activity. To evaluate this premise, we propose to study serially sampled blood and tumors for immune function assessment. PET-based imaging technology will guide us to sample tumor sites infiltrated with the TCR transgenic T cells.
In Aim 3 we will investigate the contribution to antitumor immunity of CD4+ cells genetically modified to recognize a tumor antigen restricted by MHC class I molecules (a cell type that does not exist in nature). We will determine their ability to serve as effective helper cells for CD8+ cytotoxic T lymphocytes (CTL) and rule out the possibility that they become induced suppressor Treg (iTreg). In summary, we propose to test tumor antigen-specific TCR transgenic cell adoptive transfer in a bench-tobedside and bedside-to-bench clinical research project.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
California Institute of Technology
United States
Zip Code
Siegler, Elizabeth L; Kim, Yu Jeong; Chen, Xianhui et al. (2017) Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers. Mol Ther 25:2607-2619
Han, Xiaolu; Bryson, Paul D; Zhao, Yifan et al. (2017) Masked Chimeric Antigen Receptor for Tumor-Specific Activation. Mol Ther 25:274-284
Fendler, Wolfgang Peter; Barrio, Martin; Spick, Claudio et al. (2017) 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients. J Nucl Med 58:307-311
Bryson, Paul D; Han, Xiaolu; Truong, Norman et al. (2017) Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth. Vaccine 35:5842-5849
Bethune, Michael T; Gee, Marvin H; Bunse, Mario et al. (2016) Domain-swapped T cell receptors improve the safety of TCR gene therapy. Elife 5:
Fendler, Wolfgang Peter; Czernin, Johannes; Herrmann, Ken et al. (2016) Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites. J Nucl Med 57:2016-2021
Fang, Jinxu; Xiao, Liang; Joo, Kye-Il et al. (2016) A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice. Int J Cancer 138:1013-23
Spick, Claudio; Herrmann, Ken; Czernin, Johannes (2016) 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients. J Nucl Med 57:420-30
Fiacco, Stephen V; Kelderhouse, Lindsay E; Hardy, Amanda et al. (2016) Directed Evolution of Scanning Unnatural-Protease-Resistant (SUPR) Peptides for in Vivo Applications. Chembiochem 17:1643-51
Fang, Jinxu; Hu, Biliang; Li, Si et al. (2016) A multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma. Mol Ther Oncolytics 3:16007

Showing the most recent 10 out of 64 publications